Probiodrug Ag

Astrid Kehlen

Hans-Ulrich Demuth

Ulrich Heiser

Stephan Schilling

Torsten Hoffmann

Jens-Ulrich Rahfeld

Michael Thormann

Andreas Treml

Michael Almstetter

Holger Cynis

Robert Sommer

Kathrin Gans

Ulf-Torsten Gaertner

Michael Wermann

Antje Hamann

Daniel Friedrich

Monique Haegele

The present invention relates in general to an inhibitor of a glutaminyl peptide cyclotransferase-like protein (QPCTL), and the use thereof for the treatment and/or prevention of an inflammatory disease or disorder selected from the group consisting of (a) chronic and acute inflammations, e.g. rheumatoid arthritis, atherosclerosis, restenosis, pancreatitis; (b) other inflammatory diseases, e.g. neuropathic pain, graft rejection/graft failure/graft vasculopathy, HIV infections/AIDS, gestosis, tuberous sclerosis, Guillain-Barr&#xe9; syndrome, chronic inflammatory demyelinizing polyradiculoneuropathy and multiple sclerosis; (c) neuroinflammation; and (d) neurodegenerative diseases, e.g. mild cognitive impairment (MCI), Alzheimer's disease, neurodegeneration in Down Syndrome, Familial British Dementia, and Familial Danish Dementia, which may result from neuroinflammation.

Use of isoQC inhibitors in the treatment and prevention of inflammatory diseases or conditions

Growing community of inventors

Halle/Saale, Germany

Astrid Kehlen